Taflotan, the first preservative-free prostaglandin F2α analogue: treatment advantages in primary open-angle glaucoma patients

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Over the past 15 years, the negative role of toxic preservatives in the IOP-lowering eye drops solutions used in the treatment of primary open angle glaucoma (POAG) patients has been convincingly proven by many national and foreign experts. Therefore, there is a worldwide tendency to prescribe preferably preservative-free IOP-lowering eye drops nowadays. Taflotan is the world’s first preservative-free prostaglandin F2a analogue. In our study of POAG patients switched to Taflotan from the benzalkonium chloride-preserved latanoprost eye drops, we observed a marked decrease in corneal staining and severity of conjunctival hyperemia, as well as increase of the tear breakup time and corneal epithelium morphology improvement evaluated by confocal tomography. Thus, the drug not only effectively lowers IOP but also produces less negative effect on the tear film and eyeball surface, improving treatment tolerability.

Full Text

Restricted Access

About the authors

Sergey Yu Astakhov

First Pavlov State Medical University of St Petersburg

Email: astakhov73@mail.ru
MD, PhD, Doc.Med.Sci., professor, head of the department. Ophthalmology Department

Natalia V Tkachenko

First Pavlov State Medical University of St Petersburg

Email: natalyatkachenko@yandex.ru
MD, PhD, assistant professor. Ophthalmology department

References

  1. Алексеев В.Н., Малеванная О.А., Тубаджи Е., и др. Прогрессирующая глаукома - неизбежность или недоработка? // Глаукома. - 2012. - Т. 3. - № 11. - С. 26-31. [Alekseev VN, Malevannaya OA, Tubadzhi E, et al. Progressiruyushchaya glaukoma - neizbezhnost’ ili nedorabotka? Glaukoma. 2012; 3(11):26-31. (In Russ).]
  2. Астахов С.Ю., Ткаченко Н.В. Первый опыт применения β-болкаторов без консерванта // Офтальмологические ведомости. - 2010. - Т. 3. - № 2. - С. 66-70. [Astakhov SY, Tkachenko NV. Pervyi opyt primeneniya β-bolkatorov bez konservanta. Ophthalmology Journal. 2010;3(2):66-70. (In Russ).]
  3. Коротких С.А., Борзунов О.И. Тафлупрост у пациентов с первичной открытоугольной глаукомой развитой и далеко зашедшей стадий // Клиническая офтальмология. - 2015. - № 4. - С. 176-180. [Korotkikh SA, Borzunov OI. Tafluprost u patsientov s pervichnoi otkrytougol’noi glaukomoi razvitoi i daleko zashedshei stadii. Klinicheskaya Oftal’mologiya. 2015;(4):176-180. (In Russ).]
  4. Петров С.Ю., Сафонова Д.М. Тафлупрост - первый аналог простагландинов без консерванта // Клиническая офтальмология. - 2014. - Т. 14. - № 3. - С. 166-171. [Petrov SY, Safonova DM. Tafluprost - pervyi analog prostaglandinov bez konservanta. Klinicheskaya oftal’mologiya. 2014;14(3):166-171. (In Russ).]
  5. Янченко С.В., Еременко А.И. Особенности морфологического статуса конъюктивы «глазной поверхности» у больных открытоугольной глаукомой, длительно получавших инстилляции β-блокаторов с консервантом, в условиях вторичного синдрома «сухого глаза»// Клинич. офтальмология. - 2008. - Т. 9. - № 4. - С. 133-135. [Yanchenko SV, Eremenko AI. Osobennosti morfologicheskogo statusa kon»yuktivy “glaznoi poverkhnosti” u bol’nykh otkrytougol’noi glaukomoi, dlitel’no poluchavshikh instillyatsii β-blokatorov s konservantom, v usloviyakh vtorichnogo sindroma “sukhogo glaza”. Klinicheskaya Oftal’mologiya. 2008;9(4):133-135. (In Russ).]
  6. Baratz KH, Nau CB, Winter EJ, et al. Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the ocular hypertension treatment study. Cornea. 2006;25(9):1046-52. doi: 10.1097/01.ico.0000230499.07273.c5.
  7. Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312-34. doi: 10.1016/j.preteyeres.2010.03.001.
  8. Baudouin C, Liang H, Hamard P, et al. The Ocular Surface of Glaucoma Patients Treated over the Long Term Expresses Inflammatory Markers Related to Both T-Helper 1 and T-Helper 2 Pathways. Ophthalmol. 2008;115(1):109-15. doi: 10.1016/j.ophtha.2007.01.036.
  9. Brignole-Baudouin F, Riancho L, Liang H, et al. In vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost/timolol fixed combination and latanoprost/timolol fixed combination. J Ocul Pharmacol Ther. 2011;27(3):273-80. doi: 10.1089/jop.2010.0111.
  10. Broadway D, Grierson I, O’Brien C, et al. Adverse effects of topical antiglaucoma medicaition. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446-54. doi: 10.1001/archopht.1994.01090230060021.
  11. Burstein NL. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc UK. 1985;104(4):402-9.
  12. Charnock C. Are multidose over-the-counter artificial tears adequately preserved? Cornea. 2006;25(4):432-7. doi: 10.1097/01.ico.0000183538.53017.69.
  13. De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40:619-30.
  14. Debbasch C, Brignole F, Pisella PJ, et al. Quaternary ammoniums’ and other preservatives’ contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci. 2001:42(3):642-52.
  15. Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008;246(11):1593-1601. doi: 10.1007/s00417-008-0881-9.
  16. Fernández Jiménez-Ortiz H, Toledano Fernández N, Fernández Escamez CS, et al. The effects of ocular hypotensive drugs on the cornea: an in vivo analysis with confocal microscopy. Arch Soc Esp Oftalmol. 2013;88(11):423-32.
  17. Fogagnolo P, Dipinto A, Vanzulli E, et al. A 1-Year Randomized Study of the Clinical and Confocal Effects of Tafluprost and Latanoprost in Newly Diagnosed Glaucoma Patients. Adv Ther. 2015;32:356-69. doi: 10.1007/s12325-015-0205-5.
  18. Guenoun JM, Baudouin C, Rat P, et al. In vitro Comparison of Cytoprotective and Antioxidative Effects of Latanoprost, Travoprost, and Bimatoprost on Conjunctiva-Derived Epithelial Cells. Invest Ophthalmol Vis Sci. 2005;46(12):4594-9. doi: 10.1167/iovs.05-0776.
  19. Ito T, Ohguro H, Mamiya K, et al. Effects of Antiglaucoma Drops on MMP and TIMP Balance in Conjunctival and Subconjunctival Tissue. Invest Ophthalmol Vis Sci. 2006;47(3):823-30. doi: 10.1167/iovs.05-0902.
  20. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17(3):341-9.
  21. Kanamori A, Naka M, Fukuda M, et al. Tafluprost protects rat retinal gan- glion cells from apoptosis in vitro and in vivo. Graefes Arch Clin Exp Ophthalmol. 2009;247(10):1353-60. doi: 10.1007/s00417-009-1122-6.
  22. Kashiwagi K, Tsukamoto K, Suzuki M, Tsukahara SJ. Effects of isopropyl unoprostone and latanoprost on melanogenesis in mouse epidermal melanocytes. Glaucoma. 2002;11(1):57-64. doi: 10.1097/00061198-200202000-00011.
  23. Kawa JE, Higginbotham EJ, Chang IL, et al. Effects of antiglaucoma medications on bovine trabecular meshwork cells in vitro. Exp Eye Res. 1993;57(5):557-65. doi: 10.1006/exer.1993.1160.
  24. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350-355. doi: 10.1097/IJG.0b013e31815c5f4f.
  25. Liang H, Baudouin C, Pauly A. et al. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02 % benzalkonium chloride. Br J Ophthalmology. 2008;92(9):1275-82. doi: 10.1136/bjo.2008.138768.
  26. Martone G, Frezzotti P, Tosi GM, et al. An In Vivo Confocal Microscopy Analysis of Effects of Topical Antiglaucoma Therapy With Preservative on Corneal Innervation and Morphology. Am J Ophthalmol. 2009;147(4):725-35. doi: 10.1016/j.ajo.2008.10.019.
  27. Mastropasqua L, Agnifili L, Fasanella V, et al. Conjunctival goblet cells density and preservative- free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study. Acta Ophthalmol. 2013:91:e397-e405. doi: 10.1111/aos.12131.
  28. Nakajima T, Matsugi T, Goto W, et al. New fluoroprostaglandin F2α derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypoten- sive agents. Biol Pharm Bull. 2003;26(12):1691-5. doi: 10.1248/bpb.26.1691.
  29. Niederer RL, Perumal D, Sherwin T, McGhee CN. Age-related differences in the normal human cornea: a laser scanning in vivo confocal microscopy study. Br J Ophthalmol. 2007;91(9):1165-9. doi: 10.1136/bjo.2006.112656.
  30. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23(5):490-6. doi: 10.1097/01.ico.0000116526.57227.82.
  31. Olthoff CM, Schouten JS, Van de Brone BW, et al. Non-compliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmology. 2005;112(6):953-61. doi: 10.1016/j.ophtha.2004.12.035.
  32. Pfeiffer N, Traverso CE, Lorenz K, Astakhov Y, Boiko EA. 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015 % and Timolol 0.5 % versus Each of Its Individual Preservative-Free Components. Adv Ther. 2014;31(12):1228-46. doi: 10.1007/s12325-014-0163-3.
  33. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, a san ocular hypotensive drug. Exp Eye Res. 2004;74(4):767-76. doi: 10.1016/j.exer.2003.12.007.
  34. Tsuda S, Yokoyama Y, Chiba N, et al. Effect of topical tafluprost on optic nerve head blood flow in patients with myopic disc type. J Glaucoma. 2013;22(5):398-403. doi: 10.1097/IJG.0b013e318237c8b3.
  35. Uesugui E, Dantas PE, Nishiwaki-Dantas MC, et al. Antibacterial activity of anesthetic solutions and preservatives: an in vitro comparative study. Cornea. 2000;19(3):353-4. doi: 10.1097/00003226-200005000-00019.
  36. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88(3):329-36. doi: 10.1111/j.1755-3768.2010.01907.x.
  37. Yu AL, Fuchshofer R, Kampik A, et al. Effects of Oxidative Stress in Trabecular Meshwork Cells Are Reduced by Prostaglandin Analogues. Invest Ophthalmol Vis Sci. 2008;49(11):4872-80. doi: 10.1167/iovs.07-0984.
  38. Zimmerman TJ, Hahn SR, Gelb L, et al. The Impact of Ocular Adverse Effects in Patients Treated with Topical Prostaglandin Analogs: Changes in Prescription Patterns and Patient Persistence. J Ocu Pharm Ther. 2009;25:49-56. doi: 10.1089/jop.2008.0072.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Astakhov S.Y., Tkachenko N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-65574 от 04 мая 2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies